FDA Approves Sanofi's Enzyme Therapy For Late-Onset Pompe Disease

The FDA has approved Sanofi's SA SNY Nexviazyme (avalglucosidase alfa-ngpt) to treat patients one year of age and older with late-onset Pompe disease.
Pompe disease is a progressive and debilitating muscle disorder that impairs a person's ability to move and breathe.
Nexviazyme is an enzyme replacement therapy (ERT) designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of enzyme replacement therapy in Pompe disease.
Price Action: SNY shares are up 0.2% at $50.66 during the market session on the last check Friday.
Related content: Benzinga's Full FDA Calendar.

Momentum72.11

Growth29.30

Quality71.48

Value50.13

Short

Medium

Long